Filing Flows › Health Care › Citius Oncology (CTOR)
Citius Oncology (CTOR) earnings and revenue breakdown
Latest: Q3 FY26 · 10-Q filed Aug 14, 2026 · Citius Oncology (CTOR) Q3 FY26 earnings results →
Q3 FY26 597¢ of every $1 of revenue lost · operating margin -583.5%
Citius Oncology made $1.5M in Q3 FY26. Operating margin -583.5%, net loss $8.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.5M in Q3 FY26, down 10% from the previous quarter.
Gross margin was 67.1%. Operating costs exceeded revenue by $8.7M, an operating margin of -583.5%. The quarter ended with a net loss of $8.9M, narrower than the previous quarter's $26.6M loss.
Operating cash flow was −$2.7M. Non-cash charges added back $3.6M of share-based compensation. Working capital and other items added $2.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 FY26 | 10-Q | Aug 14, 2026 | $1.5M | — | -583.5% | −$8.9M | −$2.7M |
| Q2 FY26 | 10-Q | May 15, 2026 | $1.7M | — | n/m | −$26.6M | −$3.8M |
| Q1 FY26 | 10-Q | Feb 13, 2026 | $3.9M | — | -133.2% | −$5.5M | −$7.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Citius Oncology
The Company, headquartered in Cranford, New Jersey, is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. The Company’s strategy centers on achieving a market leading position by advancing innovative therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies.
In its own words, from its 10-K, filed Dec 23, 2025.
Citius Oncology against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -583.5% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CTOR Citius Oncology | Q3 FY26 | $1.5M | — | -583.5% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Citius Oncology 10-Q on SEC EDGAR · CIK 1851484 · Pharmaceutical Preparations
13F: who owns CTOR and who is buying
More on CTOR
History
Every quarter: Q3 FY26 results · Q2 FY26 results · Q1 FY26 results
Compare CTOR with
- Citius Oncology vs Polomar Health Services (CTOR vs PMHS)
- Citius Oncology vs Citius Pharmaceuticals (CTOR vs CTXR)
- Citius Oncology vs Aclaris Therapeutics (CTOR vs ACRS)
- Citius Oncology vs Vistagen Therapeutics (CTOR vs VTGN)
- Citius Oncology vs Citius Pharmaceuticals (CTOR vs CTXR)
- Citius Oncology vs Roivant Sciences (CTOR vs ROIV)